Illumina (NASDAQ: ILMN) shareholders may be in for a rude surprise. Suitor Roche could be close to walking away from a $6.8 billion offer which values the gene research company’s shares at $51. The Illumina board has pressed for a much, much higher price backed by the argument that the firm’s technology could be among the most important for medical research over the coming decades.
Roche’s tender offer expires on Friday. Illumina’s share price jumped from $32 to $55 in early January after the first Roche offer was made. Investors have become increasingly pessimistic in the last week as shares have fallen to $45.
Illimina’s management will quickly have to prove that the firm is worth $51 all on its own based on earnings and a perception of future prospects
Take This Retirement Quiz To Get Matched With An Advisor Now (Sponsored)
Are you ready for retirement? Planning for retirement can be overwhelming, that’s why it could be a good idea to speak to a fiduciary financial advisor about your goals today.
Start by taking this retirement quiz right here from SmartAsset that will match you with up to 3 financial advisors that serve your area and beyond in 5 minutes. Smart Asset is now matching over 50,000 people a month.
Click here now to get started.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
